Ipsen’s Q3 sales came in ahead of both the AV and consensus expectations. Healthy growth was witnessed in Neuroscience while Oncology was resilient, despite’s Somatuline’s erosion. While Somatuline headwinds remain an unchanged reality, given the healthy momentum for the existing offerings, a strong line-up of potential assets and balance sheet flex to further expedite (external) innovation initiatives, Ipsen remains a well-differentiated and attractive small pharma in our coverage.
27 Oct 2022
Healthy Q3 sales; guidance reiterated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy Q3 sales; guidance reiterated
Ipsen’s Q3 sales came in ahead of both the AV and consensus expectations. Healthy growth was witnessed in Neuroscience while Oncology was resilient, despite’s Somatuline’s erosion. While Somatuline headwinds remain an unchanged reality, given the healthy momentum for the existing offerings, a strong line-up of potential assets and balance sheet flex to further expedite (external) innovation initiatives, Ipsen remains a well-differentiated and attractive small pharma in our coverage.